Gevokizumab 

Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)^[1][2].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

IL-1b

Gevokizumab (5 nM; 16 h) shows inhibitory effects of IL-1β-mediated NF-kB activation caused by the soluble receptors, sIL-1RI and sIL-1RII in HeLa cells^[1].
Gevokizumab (1.85, 5.55, 16.66, and 50 nM) is a selective negative allosteric modulator which reduces the binding affinity of sIL-1RI to IL-1β^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3553  [NCBI]

P01584

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.12 kDa

1129435-60-4

Liquid

Colorless to light yellow

[Gevokizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• 
  Loaded Gevokizumab on AHC2 biosensor, can bind TIM-3/HAVCR2 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78217) with an affinity constant of 6.595E-10 M as determined in BLI assay.
• 
  Flow cytometric analysis of 1.5X10⁶ RAW264.7 cells treated with 50 nM phorbol-12-myristate-13-acetate (PMA, HY-18739) and 5 μg/ml lipopolysaccharide (LPS, HY-D1056) for 24 hours labeling Gevokizumab (HY-P99171, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, Human IgG2 kappa, Isotype Control (HY-P99002, blue) was used as the isotype control ,cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Issafras H, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014 Jan;348(1):202-15.   [Content Brief]

  [2]. Roubille F, et al. The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014 Oct;236(2):277-85.  [Content Brief]